Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cannabis Effects on Brain Morphology in Aging (CAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01874886
Recruitment Status : Active, not recruiting
First Posted : June 11, 2013
Last Update Posted : April 22, 2019
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Alison Burggren, University of California, Los Angeles

Brief Summary:

Marijuana (Cannabis sativa) is the most widely used illicit drug worldwide, with 17.4 million Americans reporting past month use in 2010 and 4.6 million meeting criteria for dependence, underscoring the public health importance of understanding the biological implications of use. How heavy cannabis use affects brain structure and cognitive performance in late life is unknown. The ongoing maturation in the adolescent brain, including the developmental circuitry underlying memory performance and executive control puts the adolescent brain at high risk for detrimental effects of heavy cannabis use. With the aging of the 'baby boomer' generation, many people who used cannabis heavily as adolescents are now entering their senior years when age-related cognitive decline may begin. Cannabis use doubled in less than a decade during the 1970's when 38% of those surveyed in the U.S. Survey on Drug Abuse reported using cannabis and 12% of those users reported using cannabis more than 20 times a month. Understanding how heavy, early cannabis use may affect neurobiological and cognitive outcomes is of high importance for this aging population, which is already at risk for memory and cognitive deficits in aging. Because cannabis use appears to have a primary effect within the hippocampus, the main structure for memory and the structure affected most by age-related memory impairments and pre-clinical Alzheimer's disease, we expect that the effects of chronic cannabis use may be greatest during aging. To our knowledge, no study has investigated the long-term effects of adolescent cannabis use on hippocampal morphology and cognitive performance in an aging population.

Investigators will investigate hippocampal integrity and cognitive performance using high-resolution magnetic resonance imaging (MRI), diffusion tensor imaging (DTI) and neuropsychological testing in an aging population of subjects (55-70 years old) who used cannabis more than 20 times a month for at least a year during adolescence. Investigators will compare data collected from heavy cannabis users to subjects who did not use cannabis but are matched for age, gender, education, light tobacco and light alcohol use. Finally, because family history and genetic risk are known to accelerate hippocampal morphology and memory decline in aging, the investigators will investigate whether possession of the APOE ε4 variant in heavy cannabis users is synergistically related to thinner hippocampal cortex and white matter deficits.


Condition or disease
Study Focuses on Brain Morphology and Cognition in Older Subjects

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Effects of Heavy Adolescent Cannabis Use on Brain Morphology in Aging
Actual Study Start Date : January 2013
Actual Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana

Group/Cohort
Cannabis users
⋄Heavy Marijuana Users : 60-80 years old; Marijuana use initiated in adolescence with marijuana use of no more than 1-2 x/month after 30 years of age; Used marijuana more than 20 times/month for at least 1 year during this period. Cigarette smoking (tobacco) and alcohol will be allowed in both groups, which will be matched on number of smokers and nicotine dependence, measured according to the Fagerstrőm Test for Nicotine Dependence. Light alcohol use will also be allowed in and matched across both groups (< 14 drinks/week for men; < 7 drinks/week for women; may not meet DSM-IV criteria for alcohol dependence).
Clean or Non-Users
⋄No marijuana use, may smoke cigarettes, fewer than 7 drinks/week (women) or 14 drinks/week (men). 60-80 years old.



Primary Outcome Measures :
  1. Magnetic resonance imaging of hippocampal size [ Time Frame: Participants will complete an MRI scan which will take approximately 1 hour ]
    Investigators will identify sources of structural differences in aging, heavy cannabis users compared to non-users with high resolution MRI to assess subtle MTL morphology.

  2. Diffusion tensor imaging (DTI) to investigate white matter structure [ Time Frame: Participants will complete an MRI scan with DTI sequence which will take approximately 1 hour ]
    Investigators will identify sources of structural differences in aging, heavy cannabis users compared to non-users with HARDI-DTI to investigate white matter structure.

  3. Cognitive performance in a range of neuropsychological tests [ Time Frame: Neuropsychological testing will take approximately 3 hours ]
    Investigators will use neuropsychological testing to assess episodic encoding and delayed memory performance. Investigators will also investigate whether any long-term cognitive deficits relate to gray matter or white matter deficits.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects will be a community sample within the Los Angeles area. They will be recruited from the greater Los Angeles area using flyer postings in various areas of Los Angeles. Also, flyers will be posted in the Alzheimer's Disease Research Center at UCLA and the Longevity Center at UCLA as well as across the UCLA campus.
Criteria

Inclusion Criteria

  • Subjects will be 60 heavy users or non-users between 60-80 years of age
  • Participants who used marijuana during adolescence. Current marijuana usage not allowed and subjects must complete urine screening at the time of inclusion.

Exclusion Criteria

  • Major psychiatric disorders, such bipolar disorder or schizophrenia as revealed by the Structured Clinical Interview for DSM-IV Disorders (100) and exclude for confounding psychiatric conditions
  • Evidence of untreated depression as determined by a HAM-D Score of >12 (17-item version) or untreated anxiety by a score of > 8 on the Hamilton Anxiety Scale
  • Evidence of neurologic or other physical illness that could produce cognitive deterioration.
  • Volunteers with a history of TIAs, carotid bruits, or lacunae on MRI scan will be excluded
  • History of myocardial infarction within the previous year or unstable cardiac disease
  • Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100)
  • History of significant liver disease
  • Clinically significant pulmonary disease, diabetes, or cancer
  • Because medications can affect cognitive functioning, subjects needing medicines that could influence psychometric test results will be excluded. These include: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, systemic corticosteroids, benzodiazepines, medications with significant cholinergic or anticholinergic effects, anticonvulsants, or warfarin, and any affecting the serotonin system, which may affect neuropsychological test results.
  • Current diagnosis or history of alcoholism or dependence on any illicit drugs other than marijuana.
  • Use of any investigational drugs within the previous month or longer, depending on drug half-life.
  • Contraindication for MRI scan (e.g. metal in body, claustrophobia).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01874886


Locations
Layout table for location information
United States, California
UCLA Semel/Resnick Neuropsychiatric Institute
Los Angeles, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alison Burggren, Assistant Researcher, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01874886     History of Changes
Other Study ID Numbers: 431587-AZ-29944
1K01DA034728-01 ( U.S. NIH Grant/Contract )
First Posted: June 11, 2013    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: April 2019
Keywords provided by Alison Burggren, University of California, Los Angeles:
Magnetic resonance imaging
Diffusion tensor imaging
Hippocampus
Cannabis
Geriatrics
Neuropsychology
Apolipoprotein E
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders